Stivarga (Regorafenib) Patent Expiration, LOE Window & CMS Spending
Stivarga (Regorafenib) by Bayer: FDA Orange Book core substance LOE 2032-07-09, 0 AB generics, $120.9M 2024 CMS Part D & Medicaid spend, and 10 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Bayer |
| FDA Application & Pathway | N203085 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | 2032-07-09 |
| Last Listed Patent or Exclusivity Date | 2032-07-09 |
| Orange Book Patents (*PED Extensions) | 4 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $120.9M |
| 2024 Medicare Part D Spend | $96.4M |
| 2024 Medicaid Spend | $24.5M |
| Reported Wholesale Price Change (CA SB 17) | 10 WAC filings (max 22.3% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Bayer across sibling Meru public-data platforms.
- Predicate Ledger FDA 510(k)Bayer FDA 510(k) & Recall Cohortdevices.meruai.co →
- Protocol Ledger NIH ClinicalTrials.govBayer Clinical Trials & Approvalstrials.meruai.co →
- ERISA Ledger DOL Form 5500Bayer 401(k) & Form 5500 Planerisa.meruai.co →
- Plume Ledger EPA TRI & RCRABayer U.S. TRI & RCRA Facilitieshazmat.meruai.co →